1 / 4

What anti-tumor response rate should be anticipated from BRAF inhibition?

What anti-tumor response rate should be anticipated from BRAF inhibition?. A nd how should response best be assessed?. Vemurafenib or DTIC (BRIM3 ): Best t umor r esponse by individual p atient. Sum of t umor d iameters (% change from b aseline ). >100. M1c.

urit
Download Presentation

What anti-tumor response rate should be anticipated from BRAF inhibition?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. What anti-tumor response rate should be anticipated from BRAF inhibition? And how should response best be assessed?

  2. Vemurafenib or DTIC (BRIM3):Best tumor response by individual patient Sum of tumor diameters (% change from baseline ) >100 M1c Vemurafenib: 48.4% response 50 0 -50 -100 >100 DTIC: 5.5% response 50 0 -50 -100 Chapman et al, N Engl J Med 2011; 364: 2507-2516

  3. BRAFi-naïve patients:Investigator-assessed maximum tumor reduction withcombined BRAF / MEK inhibition Maximum reduction frombaseline measurement (%) 100 Dabrafenib 150 mg BID/Trametinib 2mg QD Best unconfirmed response 80 Complete response 60 Partial response Stable disease 40 Progressive disease 20 Part B Part C 0 –20 –40 –60 –80 –100 Sosman et al, ASCO 2013; 9005

  4. Response rates with BRAF inhibition The BRAF inhibitors all have ~50% response rate, with few CRs 80–90% of patients will have stable or regressed disease Results seen similar with vemurafenib, dabrafenib, and LGX 818 RECIST is the most reasonable system devised to assess response with BRAF inhibition

More Related